Biomarkers and Therapeutic Targets for Abnormal Retinal Pigment Epithelium

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Categories: “Medical and Research Devices

Reference #: 2014-007

OTC Contact: Sharon E. Pula, Esq. (Directory Information | Send a Message)

DESCRIPTION

The invention provides a method of determining if the retinal pigment epithelium (RPS) of a subject is abnormal. Abnormal RPE is present in numerous retinal diseases such as Age Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)

APPLICATIONS

ADVANTAGES

BACKGROUND

Researchers at Georgetown University have shown that low levels of miR-184 are indicative that the subject’s RPE is abnormal. Abnormal RPE plays a role in a variety of conditions such as AMD or RP and thus the present invention provides a method for determining if a subject has developed or is at risk for developing such a condition.

STAGE OF DEVELOPMENT

Investigators have proven the correlation in lab setting using human cell cultures. 

INVENTOR

Nady Golestaneh

PATENT STATUS

US Patent No. 11,008,617